摘要
第一部分贫血、吸烟、饮酒与放疗的食管鳞癌初治患者预后关系的临床研究
研究背景及目的：根据全球流行病学资料统计,食管癌是世界上最常见的癌症之一,发病率位于第八位,是世界癌症相关死亡的第六大病因。食管癌的发病率和死亡率有明显的地域性差异,除了日本以外发达国家食管癌的发病率都比较低,而我国发生的食管癌病例占全球的一半左右,是世界上食管癌发病率和死亡率最高的国家,是我国癌症相关死亡的第四大病因。食管癌主要分为两种组织学类型：食管鳞状细胞癌和食管腺癌。食管鳞状细胞癌仍然是中国和其他东亚国家食管癌的主要类型,而食管腺癌主要发生在美国和欧洲国家的白种人。
目前食管癌的治疗中,手术治疗仍为首选治疗,具有重要的地位。不能手术和局部晚期患者,放射治疗为标准治疗,目前多主张同步放化疗。手术切除可以根治早期食管癌,对于局部进展期食管癌,仍然具有切除临床病灶、缓解梗阻、延长生存期的作用。但以手术为主的治疗模式,局部复发及远处转移率较高,总体预后差。治疗失败的主要原因在于局部复发和远处转移。由于食管在纵隔中与重要组织器官相邻,影响了肿瘤的完整切除,同时在确诊食管癌时常已存在微转移病灶,这为肿瘤的局部复发和远处转移创造了条件,从而影响了手术的疗效。食管癌,尤其是食管鳞癌对射线中度敏感,放疗可控制食管癌的局部复发,而同步应用的化疗既可以加强放疗控制局部肿瘤病灶,也可以消灭全身的微转移病灶,可减少肿瘤的复发和转移,为食管癌的治疗带来了希望。近来研究发现手术联合放化疗可延长可切除食管癌患者的长期生存率。
放疗作为食管癌主要的治疗手段之一,提高放疗疗效,增加局部控制率,从而提高生存率。肿瘤细胞是否乏氧及乏氧克隆细胞所占的比例是影响放射敏感性的主要因素。有研究证明贫血可以引起肿瘤组织乏氧,通过一些肿瘤基因的活动,如基因不稳定性,基因突变,紊乱增生；X射线对哺乳动物细胞DNA的损伤,约三分之二是由氢氧自由基所致；肿瘤组织乏氧时由于氧气的缺乏导致自由基产生下降,从而减少肿瘤细胞DNA损伤,产生放射抗拒。Fein等报道在T12期声门鳞癌患者中,血红蛋白正常组的2年局部控制率明显优于贫血组。然而,在贫血与食管鳞癌预后关系方面的研究却罕见报道。吸烟、饮酒早已经被认为是食管鳞癌发病的主要危险因素,然而,却很少有研究报道吸烟、饮酒是否会影响食管鳞癌患者的预后。本研究的目的是评价贫血、吸烟、饮酒在初治的食管鳞癌放疗患者中的预后价值及与其他预后因子的关系。
研究方法：本研究收集了2009年1月至2010年12月山东大学齐鲁医院放疗科收治的经病理证实、有完整随访资料的79例初次治疗的食管癌患者的临床资料,经病理学检查证实均为鳞癌,且都接受了放疗。采用直线加速器,技术为三维适形放疗,照射靶区主要包括原发灶和区域淋巴结,术前或术后一般剂量为50Gy,未行手术治疗的患者一般剂量为60-70Gy。化疗方案为紫杉类药物联合铂类方案。贫血的定义：男性血红蛋白<120g/L,女性血红蛋白<110g/L。用SPSS17.0统计软件进行分析。患者2年总生存率和2年无复发生存率情况用Kaplan-Meier方法进行分析；生存率比较用log-rank检验。临床指标(年龄、性别、是否吸烟、TNM分期、治疗方式、肿瘤部位等)和贫血对2年总生存率和无复发生存率的分析采用Cox回归进行单因素、多因素分析；P<0.05为有统计学意义。
研究结果：在79例放疗的食管鳞癌初治患者中,治疗前贫血的发病率为29.1%,贫血组和血红蛋白正常组两组患者在临床资料、肿瘤特征、治疗方面没有统计学差异。血红蛋白正常组2年总生存率和2年无复发生存率分别为36%、25%,贫血组2年总生存率和2年无复发生存率分别为17%、13%,两者差异有统计学意义(总生存率P=0.019；无复发生存率P=0.029)。是否吸烟组和是否饮酒组2年总生存率和2年无复发生存率,两者差异无统计学意义。单因素分析发现贫血可影响患者的2年总生存率(风险比=1.897；P＝0.024)和2年无复发生存率(风险比=1.776；P=0.036)。多因素分析提示贫血可影响患者的2年总生存率(风险比=2.125；P=0.011)和2年无复发生存率(风险比=1.898；P=0.025)。单因素和多因素分析发现是否吸烟和是否饮酒对2年总生存率和2年无复发生存率的影响均无统计学意义。
研究结论：放疗前的贫血是影响放疗的食管鳞癌初治患者2年总生存率和2年无复发生存率的一个独立预后因素,可增加复发的风险。血常规是一项常规检查,在临床中可简单而快速的判断是否贫血。
第二部分体重指数与放化疗的食管鳞癌初治患者预后关系的临床研究
研究背景及目的：根据全球流行病学资料统计,食管癌是全球最常见肿瘤之一其发病率居第八位、病死率居第六位。食管癌主要分为两种组织学类型：食管鳞状细胞癌和食管腺癌。中国和其他亚洲国家以食管鳞癌为主,而在美国和欧洲国家,腺癌更常见。目前在中国,随着经济的发展,肥胖的人数也在不断增加。有些研究发现体重指数的增加明显增加了乳腺癌、胰腺癌、结直肠癌和食管癌的发病风险。Carmichael A. R等发现无论是绝经期前还是绝经期后,肥胖的女性乳腺癌患者预后较低/正常体重的乳腺癌患者差。在一项4288例结肠癌患者的研究中,在诊断结肠癌时体重指数大于35.0kg/m2患者更容易出现肿瘤的复发,预后较差。Pelucchi C等发现在诊断胰腺癌时体重指数大于25.0kg/m2的患者较体重指数小于等于25.0kg/m2的患者生存率明显下降。然而,也有一些学者证明体重指数与癌症患者的预后无明显相关性。Hayashi Y等的研究显示,超重/肥胖体重指数的患者与正常/低体重指数的患者相比,超重/肥胖体重指数患者的5年总生存率和5年无复发生存率更高的原因是超重/肥胖体重指数的患者在诊断食管癌时临床分期较早。Ravi Shridhar等报道在放化疗的食管腺癌患者中,体重指数与患者的生存无明显相关性。目前体重指数与食管鳞癌预后关系的临床研究尚少。本实验的目的是评估治疗前的体重指数在放化疗的食管鳞癌初治患者中预后的价值。
研究方法：本研究收集了2009年1月至2010年12月山东大学齐鲁医院放疗科和淄博市第一医院肿瘤科收治的经病理证实、有完整随访资料的60例初次治疗的食管癌患者的临床资料,经病理学检查证实均为鳞癌,且都接受了同步放化疗,化疗方案为多西紫杉醇+顺铂(21天为一周期,共2周期),同时给予三维适形放疗,DT54-60Gy/2Gy/27-30F,同步放化疗结束后继续原方案化疗3-4周期。我们根据体重指数将病人分成体重指数小于24.00kg/m2和体重指数大于等于24.00kg/m2两组,对比两组患者2年总生存率和无复发生存率情况；P<0.05为有统计学意义。
研究结果：共有60例食管鳞癌患者进入本研究,其中41例患者在低/正常体重组(体重指数小于24.00kg/m2),19例患者在超重/肥胖体重组(体重指数大于等于24.00kg/m2)。两组患者在临床资料、肿瘤特征、治疗方面没有统计学差异。我们应用Kaplan-Meier生存函数分析发现低/正常体重组和超重/肥胖体重组的2年总生存率和2年无复发生存率无统计学意义(P=0.763for OS;P=0.818for DFS)。 Cox单因素分析发现临床分期可影响患者的2年总生存率和2年无复发生存率,淋巴结状态可影响患者的2年无复发生存率,远处转移情况可影响患者的2年总生存率,而年龄、性别、是否吸烟、是否饮酒、肿瘤部位和体重指数与患者的2年总生存率和2年无复发生存率无相关性。Cox多因素分析显示,体重指数与患者的2年总生产率的风险比为1.117,2年无复发生存率的风险比为1.161,无统计学意义。Cox多因素分析显示,临床分期、性别、T分期为放化疗的食管鳞癌初治患者独立的预后因素(P<0.04)。
研究结论：体重指数与放化疗的食管鳞癌初治患者的2年总生存率和2年无复发生存率无明显相关性,体重指数不是一个放化疗食管鳞癌初治患者的预后指标。
结论：放疗前贫血是影响放疗的食管鳞癌初治患者2年总生存率和无复发生存率的一个独立预后因素,体重指数不是一个放化疗食管鳞癌初治患者的预后指标。
Part1A retrospective study:the prognostic value of anemia, smoking and drinking in esophageal squamous cell carcinoma with primary radiotherapy
Objective:Esophageal cancer is the eighth most common cancer and the sixth mortality in the world. The distribution of esophageal cancer is heterogenous. Developed countries except for Japan have low rates, while China has a high rate of esophageal cancer, the fourth mortality in China. Esophageal squamous cell carcinoma (ESCC) continues to be the major type of esophageal cancer in Asia, in contrast, esophageal adenocarcinoma predominately affects the whites. Tobacco smoking and alcohol are well established causes of ESCC; however, there are few reports that directly evaluate these factors as prognostic factors for esophageal cancer. Currently, surgery remains an important treatment choice in esophageal cancer, while concurrent chemoradiotherapy is the standard treatment in inoperable and locally advanced esophageal cancer. The main reason for treatment failure is recurrence and distant metastasis. Radiotherapy is one of the main treatment for esophageal cancer and can control local recurrence of esophageal cancer. Anaemia is known to produce rumour hypoxia, tumour hypoxia confers radio-resistance through the hypoxia-associated reduction in free-radical production and consequent radiotherapy-induced DNA damage. Fein et al reported that the2-year local control rates in the non-anaemic group were significantly better than those in the anaemic group (p<0.0018) in T1-T2squamous cell carcinoma of the glottic larynx. However, few studies have investigated the relation between anemia and survival in patients with ESCC. The objective of this study was to evaluate the prognostic value of anaemia, smoking and drinking in patients receiving primary radiotherapy for ESCC and its relationship with other prognostic factors.
Methods:A total of79patients who underwent radiotherapy during initial treatment for ESCC were included in this study. The2-year overall survival rate and disease-free survival rate were analyzed between the anemic and non-anemic groups, non-smokers and smokers groups, non-drinkers and drinkers groups using the Kaplan-Meier method and the Cox proportional hazards model.
Results:There were79patients (10female) of median age of63(range38-84) years. The2-year overall survival rate and disease-free survival rate were36%and25%, respectively, in the non-anemic group, and17%and13%, respectively, in the anemic group(P=0.019for overall survival rate; P=0.029for disease-free survival rate) using the Kaplan-Meier method. Survival analysis using the Kaplan-Meier method show that the2-year overall survival rate and disease-free survival rate were no statistical difference between smoking, drinking and survival. In a univariate analysis, anemia was identified as a significant prognostic factor for2-year overall survival rate (haz-ard ratio1.897; P=0.024) and2-year disease-free survival rate (hazard ratio1.776; P=0.036), independent of TNM stage. In a multivariate analysis, anemia was identified as a highly significant prognostic factor for2-year overall survival rate (hazard ratio2.125; P=0.011) and2-year disease-free survival rate (hazard ratio1.898; P=0.025), independent of TNM stage and initial treatment. We found no statistical difference in the2-year overall survival rate and disease-free survival rate associated with smoking(P>0.2) and drinking (P>0.6) in univariate and multivariate analysis.
Conclusions:Smoking and drinking were not prognostic for2-year overall survival rate or disease-free survival rate. Anemia before radiotherapy was associated with poor prognosis and an increased risk of relapse, which may serve as a new prognostic characteristic in ESCC treated with primary radiotherapy. Hemoglobin is a routine examination, therefore Anemia is simple and quick to determine.
Part2Prognostic Value of Body Mass Index for Patients Undergoing Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
Objective:Esophageal cancers are among the most prevalent malignancies worldwide, with high rates of incidence and mortality. There are two major histological types of esophageal carcinoma:esophageal squamous cell carcinoma (ESCC) and adenocarcinoma with considerably varied epidemiological features. ESCC continues to be the major type of esophageal cancer in Asia, whereas esophageal adenocarcinoma predominately affects the whites. In China, the ratio of obesity is increasing. In some studies increased the body mass index(BMI) has been shown to correlate with increased risk for breast, pancreatic, colorectal, and esophageal cancers. Carmichael A.R showed that obesity was associated with worse prognosis in both pre-and post-menopausal women with breast cancer. Among4288colon cancer patients, a BMI greater than35.0kg/m2at diagnosis was associated with an increased risk for recurrence of and death from colon cancer. Pelucchi C et al. found that a BMI greater than25.0kg/m2at diagnosis was associated with reduced survival after pancreatic cancer. However, others have shown that the body mass index was not of prognostic value. Hayashi Y et al. have shown that the better5-year overall survival (OS) and disease-free survival (DFS) noted in patients with a high BMI compared with those with a normal/low BMI is because of the diagnosis of a low baseline clinical stage. Ravi Shridhar et al. reported that BMI was not associated with survival in patients with esophageal adenocarcinoma treated with chemoradiotherapy (CRT). The impact of obesity on survival of ESCC has only been minimally addressed. The aim of the present study was to examine whether BMI was of the prognostic value in patients with ESCC who underwent CRT as primary treatment.
Methods:Sixty patients with ESCC were retrospectively reviewed in this study. Patients' overall survival(OS)and disease-free survival(DFS) were compared between the two groups (BMI<24.00kg/m2and BMI≥24.00kg/m2).
Results:There were41patients in the low/normal BMI group (BMI<24.00kg/m2) and19patients in the high BMI group (BMI>24.00kg/m2). No significant differences were observed in patient characteristics between groups. We found no difference in2-year OS and DFS associated with BMI (p=0.763for OS; p=0.818for DFS) using the Kaplan-Meier method. Univariate analysis revealed that higher clinical stage was prognostic for worse2-year OS and DFS, metastasis for2-year OS, Lymph node status for2-year DFS, while age, gender, smoking, drinking, tumor location and BMI were not prognostic. There were no differences in the2-year OS (hazard ratio=1.117; p=0.789) and DFS(hazard ratio=1.161; p=0.708) between BMI groups in multivariate analysis. In a multivariate analysis, We found statistical differences in the2-year OS and DFS associated with clinical stage, gender and tumor infiltration (P<0.04), independent of age, smoking, drinking, tumor location, the status of Lymph node, metastases and BMI.
Conclusions:BMI was not associated with survival in patients with ESCC treated with CRT as primary therapy. BMI should not be considered a prognostic factor for Patients undergoing CRT for ESCC.
Conclusion of the study:Anemia before radiotherapy may serve as a new prognostic characteristic in ESCC treated with primary radiotherapy. BMI should not be considered a prognostic factor for Patients undergoing CRT for ESCC.
引文
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM:Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Yamaji T, Inoue M, Sasazuki S, Iwasaki M, Kurahashi N, Shimazu T, Tsugane S; Japan Public Health Center-based Prospective Study Group:Fruit and vegetables consumption and squamous cell carcinoma of the esophagus in Japan:the JPHC study. Int J Cancer 2008,123:1935-1940.
3. Lu SH:Alterations of oncogenes and tumor suppressor genes in esophageal cancer in China. Mutat Res 2000,462:343-353.
4. Vaupel P, Thews O, Hoeckel M:Treatment resistance of solid tumours:roles of hypoxia and anemia. Med Oncol 2001,18:243-249.
5. Fein DA, Lee W R, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, Coia LR: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995,13:2077-2083.
6. Rice TW, Blackstone EH, Rusch VW:7th edition of the AJCC Cancer Staging Manual:esophagus and esophagogastric junction. Ann Surg Oncol.2010,333 17:1721-1724.
7. Walter CJ, Bell LT, Parsons SR, Jackson C, Borley NR, Wheeler JM:Prevalence and significance of anemia in patients receiving long-course neoadjuvant chemoradiotherapy for rectal carcinoma. Colorectal Dis 2013,15:52-56.
8. Dietl B, Marienhagen J, Schafer C, Kolbl O:The prognostic value of anemia at different treatment times in patients with locally advanced head and neck cancer treated with surgery and postoperative radiotherapy. Clin Oncol 2007,19:228-233.
9. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, Brugere J, Point D, Giraud P, Cosset JM:Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer:a prospective study. Radiology 1996,201:553-558.
10. Grigiene R, Aleknavicius E, Kurtinaitis J. Prognostic value of anemia for patients with cervical cancer treated with irradiation. Medicina 2005,41:916-924.
11. MacRae R, Shyr Y, Johnson D, Choy H:Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 2002,64:37-40.
12. Zenda S, Hironaka S, Boku N, Yamazaki K, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Nishimura T:Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Dis Esophagus 2008, 21:195-200.
13. Zhao KL, Liu G, Jiang GL, Wang Y, Zhong LJ, Wang Y, Yao WQ, Guo XM, Wu GD, Zhu LX, Shi XH:Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy--a secondary analysis of three consecutive clinical phase III trials. Clin Oncol 2006, 18:621-627.
14. Hofheinz RD, Raab B, Mai S, Wenz F, Willeke F, Emig M, Buchheidt D, Hehlmann R,Hochhaus A:Impact of chemoradiotherapy-induced anemia on survival in uniformly staged patients with locally advanced squamous cell carcinoma of the esophagus. Onkologie 2004,27:462-466.
15. Kandaz M, Ertekin MV, Bilici M:Retrospective analysis of patients with esophageal cancer treated with radiotherapy and/or chemoradiotherapy. Tumori 2012, 98:445-50.
16. Michalek AM, Cummings KM, Pontes JE:Cigarette smoking, tumor recurrence, and survival from bladder cancer. Prev Med 1985,14:92-98.
17. Vatten LJ, Foss OP, Kvinnsland S:Overall survival of breast cancer patients in relation to preclinically determined total serum cholesterol, body mass index, height and cigarette smoking:a population-based study. Eur J Cancer 1991,27:641-646.
18. Sundelof M, Lagergren J, Ye W:Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. Eur J Cancer 2008,44:1566-1571.
19. Samadi F, Babaei M, Yazdanbod A, Fallah M, Nouraie M, Nasrollahzadeh D, Sadjadi A, Derakhshan MH, Shokuhi B, Fuladi R, Malekzadeh R:Survival rate of gastric and esophageal cancers in Ardabil province, North-West of Iran. Arch Iran Med 2007,10:32-37.
20. Trivers KF, De Roos AJ, Gammon MD, Vaughan TL, Risch HA, Olshan AF, Schoenberg JB, Mayne ST, Dubrow R, Stanford JL, Abrahamson P, Rotterdam H, West AB, Fraumeni JF, Chow WH:Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin Gastroenterol Hepatol 2005, 3:225-230.
21. Tsai CH, Hsu HS, Wang LS, Wang HW, Wu YC, Hsieh CC, Huang BS, Hsu WH, Huang MH:Surgical results of squamous cell carcinoma of the esophagus in young patients. J Chin Med Assoc 2003,66:288-293.
22. Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P: Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer. Surgery 2013,153:526-534.
23. Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z, Tan B, Wang N, Bai B, Yang S, Liu H, Zhu S, Cheng Y:Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. J Thorac Oncol 2012,7:1457-1461.
1. Spechler SJ, Sharma P, Souza RF, Inadomi JM and Shaheen NJ, American Gastroenterological Association technical review on the management of Barrett's esophagus, Gastroenterology, vol.140, no.3, pp. e18-e52,2011.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al., Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008, Int J Cancer, vol.127, pp. 2893-2917,2010.
3. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M, Body-mass index and incidence of cancer:a systematic review and meta-analysis of prospective observational studies, Lancet,vol.371, no.9612, pp.569-578,2008.
4. Carmichael AR, Obesity and prognosis of breast cancer, Obes Rev, vol.7, no.4, pp. 333-340,2006.
5. Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, et al, Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer, J Natl Cancer Inst, vol.98, no.22, pp.1647-1654,2006.
6. Pelucchi C, Galeone C, Polesel J, Manzari M, Zucchetto A, et al., Smoking and Body Mass Index and Survival in Pancreatic Cancer Patients, Pancreas,2013 Oct 30.
7. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, et al., The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy, Cancer, vol.116, pp.5619-5627,2010.
8. Shridhar R, Hayman T, Hoffe SE, Weber J, Almhanna K, et al., Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy, J Gastrointest Surg, vol.16, pp.1296-1302,2012.
9. WHO Expert Consultation, Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies, Lancet, vol.363, pp. 157-163,2004.
10. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, et al., Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma, Dis Esophagus, 2013 Apr 26. doi:10.1111/dote.12074.
11. Grotenhuis BA, Wijnhoven BP, Hotte GJ, vander Stok EP, Tilanus HW, et al., Prognostic value of body mass index on short-term and long-term outcome after resection of esophageal cancer, World J Surg, vol.34:2621-2627,2010.
12. Trivers KF, De Roos AJ, Gammon MD, Vaughan TL, Risch HA, et al., Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers, Clin Gastroenterol Hepatol, vol.3, no.3, pp.225-230,2005.
13. Smith M, Zhou M, Whitlock G, Yang G, Offer A, et al., Esophageal cancer and body mass index:results from a prospective study of 220,000 men in China and a meta-analysis of published studies, Int J Cancer, vol.122, pp.1604-1610,2008.
14. McRackan TR, Watkins JM, Herrin AE, Garrett-Mayer EM, Sharma AK, et al., Effect of body mass index on chemoradiation outcomes in head and neck cancer, Laryngoscope, vol.118, no.7, pp.1180-1185,2008.
15. Eroglu C, Orhan O, Karaca H, Unal D, Dikilitas M, et al., The effect of being overweight on survival in patients with gastric cancer undergoing adjuvant chemoradiotherapy, Eur J Cancer Care (Engl), vol.22, no.1, pp.133-140,2013. doi: 10.1111/ecc.l2010.
16. Matsuo K, Mizoue T, Tanaka K, Tsuji I, Sugawara Y, et al., Association between body mass index and the colorectal cancer risk in Japan:pooled analysis of population-based cohort studies in Japan, Ann Oncol, vol.23, pp.479-490,2012.
17. Morrison DS, Parr CL, Lam TH, Ueshima H, Kim HC, et al. Behavioural and metabolic risk factors for mortality from colon and rectum cancer:analysis of data from the Asia-Pacific Cohort Studies Collaboration. Asian Pac J Cancer Prev, 14,1083-7,2013.
18. Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, et al., The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy, Cancer, vol.117, no.5, pp. 948-956,2011. doi:10.1002/cncr.25544.
19. Kaviani A, Neishaboury M, Mohammadzadeh N, Ansari-Damavandi M, Jamei K. Effects of obesity on presentation of breast cancer, lymph node metastasis and patient survival:a retrospective review. Asian Pac J Cancer Prev,14,2225-9,2013.
20. Gaudet MM, Patel AV, Sun J, Hildebrand JS, McCullough ML, et al., Prospective studies of body mass index with head and neck cancer incidence and mortality, Cancer Epidemiol Biomarkers Prev, vol.21, pp.497-503,2012.
21. Felden JB, Figueiredo AC, Distribution of body fat and breast cancer:a case-control study in the South of Brazil, Cien Saude Colet, vol.16, pp.2425-2433, 2011.
22. Kandaz M, Ertekin MV, Bilici M, Retrospective analysis of patients with esophageal cancer treated with radiotherapy and/or chemoradiotherapy, Tumori, vol. 98, pp.445-450,2012.
23. Samadi F, Babaei M, Yazdanbod A, Fallah M, Nouraie M, et al., Survival rate of gastric and esophageal cancers in Ardabil province, North-West of Iran, Arch Iran Med,vol.10, pp.32-37,2007.
24. Schoppmann SF, Jesch B, Zacherl J, Riegler MF, Friedrich J, et al., Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer, Surgery, no.153, pp.526-534,2013.
25. Zhang F, Han H, Wang C, Wang J, Zhang G, et al., A retrospective study:the prognostic value of anemia, smoking and drinking in esophageal squamous cell carcinoma with primary radiotherapy, World J Surg Oncol, vol.11, no.1, pp.249, 2013. doi:10.1186/1477-7819-11-249.
1. Tesarova P, Kvasnicka J. Treatment of anemia in patients with tumors. Cas Lek Cesk.1995; 134:647-650.
2. Caro JJ, Salas M, Ward A, Goss G Anemia as an independent prognostic factor for survival in patients with cancer:a systemic, quantitative review. Cancer.2001; 91: 2214-2221.
3. Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys.1995;31:1319-39.
4. Testa NG, Hendry JH, Molineux G Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy. Anticancer Res. 1985;5:101-10.
5. Shander A, Knight K, Thurer R, Adamson J, Spence R. Prevalence and outcomes of anemia in surgery:a systematic review of the literature. Am J Med.2004; 116 Suppl 7A:58S-69S.
6. Shin NR, Lee YY, Kim SH, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. Obstet Gynecol Sci.2014 Jan;57(1):28-36.
7. Obermair A, Cheuk R, Horwood K, Neudorfer M, Janda M, Giannis G, et al. Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma:effect on progression-free survival. Int J Gynecol Cancer.2003; 13:633-639.
8. Kapp KS, Poschauko J, Geyer E, Berghold A, Oechs AC, Petru E, et al. Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys.2002; 54:58-66.
9. Fyles AW, Milosevic M, Pintilie M, Syed A, Hill RP. Anemia, hypoxia and transfusion in patients with cervix cancer:a review. Radiother Oncol.2000;57:13-19.
10. Cappell MS, Goldberg ES. The relationship between the clinical presentation and spread of colon cancer in 315 consecutive patients. A significant trend of earlier cancer detection from 1982 through 1988 at a university hospital. J Clin Gastroenterol.1992; 14:227-235.
11. Sadahiro S, Suzuki T, Tokunaga N, Mukai M, Tajima T, Makuuchi H, Saito T. Anemia in patients with colorectal cancer. J Gastroenterol.1998; 33:488-494.
12. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, et al. The European Cancer Anaemia Survey (ECAS):a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer.2004; 40:2293-2306.
13. Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis.2005; 7:398-402.
14. Prutki M, Poljak-Blazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett.2006; 238:188-196.
15. Kim J, Konyalian V, Huynh R, Mittal R, Stamos M, Kumar R. Identification of predictive factors for perioperative blood transfusion in colorectal resection patients. Int J Colorectal Dis.2007; 22:1493-1497.
16. Edna TH, Karlsen V, Jullumstra E, Lydersen S. Prevalence of anaemia at diagnosis of colorectal cancer:assessment of associated risk factors. Hepatogastroenterology.2012; 59:713-716.
17. Shao L, Sun Y, Zhang Z, et al. Deletion of proapoptotic Puma selectively protects hematopoietic stem and progenitor cells against high-dose radiation. Blood.2010; 115:4707-14.
18. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood.1993; 82:1092-6.
19. Domen J, Gandy KL, Weissman IL. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the Consequences of lethal irradiation. Blood.1998; 91:2272-82.
20. Meng A, Wang Y, Brown SA, et al. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and-independent mechanisms. Exp Hematol.2003; 31:1348-56.
21. Mohrin M, Bourke E, Alexander D, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell.2010; 7:174-85.
22. Dainiak N. Hematologic Consequences of exposure to ionizing radiation. Exp Hematol.2002; 30:513-28.
23. Gardner RV, Begue R, Mckinnon E. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on primitive hematopoietic stem cell (PHSC) function and numbers, after chemotherapy. Exp Hematol.2001; 29:1053-9.
24. van Os R, Robinson S, Sheridan T, et al. Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents. Blood.1998; 92:1950-6.
25. Pineda JR, Daynac M, Chicheportiche A, et al. Vascular-derived TGF-β increases in the stem cell niche and perturbs neurogenesis during aging and following irradiation in the adult mouse brain. EMBO Mol Med.2013; 5:548-62.
26. Santos GW. Preparative regimens:chemotherapy versus chemoradiotherapy. A historical perspective. Ann N Y Acad Sci.1995; 770:1-7.
27. Meng A, Wang Y, Van Zant G, et al. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res.2003; 63:5414-9.
28. Wang Y, Schulte BA, Larue AC, et al. Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood.2006; 107:358-66.
29. van Os R, Robinson S, Sheridan T, et al. Granulocyte-colony stimulating factor impedes recovery from damage caused by cytotoxic agents through increased differentiation at the expense of self-renewal. Stem Cells.2000; 18:120-7.
30. Yu H, Shen H, Yuan Y, et al. Deletion of puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation. Blood. 2010; 115:3472-80.
31. Carbonneau CL, Despars G, Rojas-Sutterlin S, et al. Ionizing radiation-induced expression of INK4a/ARF in murine bone marrow-derived stromal cell populations interferes with bone marrow homeostasis. Blood.2012; 119:717-26.
32. Ludwig H, Fritz E. Anemia of cancer patients:patient selection and patient stratification for epoetin treatment. Semin Oncol.1998; 25(3 Suppl 7):35-38.
33. Demetri GD, Kris M, Wade J, Degos L, Cella D. Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type:results from a prospective community oncology study. J Clin Oncol.1998; 16:3412-3425.
34. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix.Cancer.1999; 86:1528-1536.
35. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med.2012; 366:610-618.
36. Sundfor K, Lyng H, Kongsgard UL, Trope C, Rofstad EK. Polarographic measurement of pO2 in cervix carcinoma. Gynecol Oncol.1997; 64:230-236.
37. Lim CL, Kim JY, Kim TH, Park S, Kong SY, Yoon JH, Kang S, Seo SS, Park SY. Allogenic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer. Yonsei Med J.2008; 49(6): 993-1003.
38. Hofheinz RD, Raab B, Mai S, Wenz F, Willeke F, Emig M, Buchheidt D, Hehlmann R,Hochhaus A. Impact of chemoradiotherapy-induced anemia on survival in uniformly staged patients with locally advanced squamous cell carcinoma of the esophagus. Onkologie.2004; 27(5):462-6.
39. Amato A and Pescatori M. Perioperative blood transfusions and the recurrence of colorectal cancer. Cochrane database of systematic reviews.2006, Issue 1. Art. No.: CD005033.
40. Nilsson KR, Berenholtz SM, Garrett-Mayer E, Dorman T, Klag MJ, Pronovost PJ. Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg.2007; 142:126-132; discussion 133.
41.Xenos ES, Vargas HD, Davenport DL. Association of blood transfusion and venous thromboembolism after colorectal cancer resection. Thromb Res.2012; 129:568-572.
42. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Erythropoietin or Darbepoetin for patients with cancer:meta-analysis based on individual patient data. Cochrane Database Syst Rev.2009; (3):CD007303.
43. Devon KM and McLeod RS. Pre and peri-operative erythropoietin for reducing allogeneic blood transfusions in colorectal cancer surgery. Cochrane database of systematic reviews.2009. Issue 1.Art. No.:CD007148.
44. Lambin P, Ramaekers BLT, Van Mastrigt GAPG, Van den Ende P, De Jong J, De Ruysscher DKM,Pijls-Johannesma M. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane database of systematic reviews.2009, Issue 3. Art. No.:CD006158.
45. Hong Man Yoon, Young-Woo Kim, Byung Ho Nam, Daniel Reim, Bang Wool Eom, Ji Yeon Park, and Keun Won Ryulntravenous iron supplementation may be superior to observation in acute isovolemic anemia after gastrectomy for cancer. World J Gastroenterol.2014; 20(7):1852-1857.
46. Vaupel P, Thews O, Hoeckel M:Treatment resistance of solid tumours:roles of hypoxia and anemia. Med Oncol 2001,18:243-249.
47. Becker A, Stadler P, Lavey RRS, Hansgen G, Kuhnt T, Lautenschlager C, Feldmann HJ, Molls M,Dunst J. Severe anaemia is associated with poor tumour oxygenation in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000; 46:459-66.
48. Harrison LB, Chadra M, Hill RJ, Hu K and Shasha D. Impact of tumor hypoxia on radiation therapy outcomes. Oncologist.2002; 7:492-508.
49. Nordsmark M, Bentzen S M, Rudat V et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol.2005; 77:18-24.
50. Dietl B, Marienhagen J, Schafer C, Kolb1 O:The prognostic value of anemia at different treatment times in patients with locally advanced head and neck cancer treated with surgery and postoperative radiotherapy. Clin Oncol.2007,19:228-233.
51. Fein DA, Lee W R, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr, Coia LR: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol.1995,13:2077-2083.
52. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, Brugere J, Point D, Giraud P, Cosset JM:Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer:a prospective study. Radiology.1996,201:553-558.
53. Obermair A, Handisurya A, Kaider A, Sevelda P, Kolbl H, Gitsch G. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients:a prospective review. Cancer.1998;83:726-731.
54. Schreiner P, Siracka E, Siracky J, Manka I. The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma.1975; 22:655-660.
55. Thomson JM, Spratt JS., Jr Factors affecting survival in over 500 patients with stage II carcinoma of the cervix. Radiology.1977; 123:181-183.
56. Kapp DS, Fischer D, Gutierrez E, Kohorn El, Schwartz PE. Pretreatment prognostic factors in carcinoma of the uterine cervix:a multivariable analysis of the effect of age, stage, histology and blood counts on survival. Int J Radiat Oncol Biol Phys.1983; 9:445-455.
57. Girinski T, Pejovic-Lenfant MH, Bourhis J, Campana F, Cosset JM, Petit C, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy:results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys.1989; 16:37-42.
58. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer.1999; 86:1528-1536.
59. Grigiene R, Aleknavicius E, Kurtinaitis J. Prognostic value of anemia for patients with cervical cancer treated with irradiation.Clin Oncol (R Coll Radiol). Medicina (Kaunas).2005; 41(11):916-24.
60. MacRae R, Shyr Y, Johnson D, Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol.2002; 64(1):37-40.
61. Xu C1, Gao Y, Li L, Xing L, Liu S. Impact of anemia on chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi.2010; 13(10):968-74.
62. Walter CJ, Bell LT, Parsons SR, Jackson C, Borley NR, Wheeler JM. Prevalence and significance of anaemia in patients receiving long-course neoadjuvant chemoradiotherapy for rectal carcinoma. Colorectal Dis.2013; 15(l):52-6.
63. Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, Khreiss M, Dahdaleh FS, Khavandi K, Sfeir PM, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery:a retrospective cohort study. Lancet.2011; 378:1396-1407.
64. Kang CY, Chaudhry OO, Halabi WJ, Nguyen V, Carmichael JC, Stamos MJ, Mills S. Outcomes of laparoscopic colorectal surgery:data from the Nationwide Inpatient Sample 2009. Am J Surg.2012; 204:952-957.
65. Zhen L, Zhe S, Zhenning W, Zhifeng M, Zhidong L, Xiaoxia L, Jianguang Y, Huimian X. Iron-deficiency anemia:a predictor of diminished disease-free survival of T3N0M0 stage colon cancer. J Surg Oncol.2012; 105:371-375.
66. Zenda S, Hironaka S, Boku N, Yamazaki K, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Nishimura T. Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer.Dis Esophagus.2008; 21(3):195-200.
67. Zhao KL, Liu G, Jiang GL, Wang Y, Zhong LJ, Wang Y, Yao WQ, Guo XM, Wu GD, Zhu LX, Shi XH. Association of haemoglobin level with morbidity and mortality of patients with locally advanced oesophageal carcinoma undergoing radiotherapy--a secondary analysis of three consecutive clinical phase III trials. Clin Oncol (R Coll Radiol).2006; 18(8):621-7.